These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Le Gal G; Kovacs MJ; Carrier M; Do K; Kahn SR; Wells PS; Anderson DA; Chagnon I; Solymoss S; Crowther M; Righini M; Lacut K; White RH; Vickars L; Rodger M Thromb Haemost; 2010 Sep; 104(3):498-503. PubMed ID: 20539910 [TBL] [Abstract][Full Text] [Related]
48. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Tosetto A; Iorio A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Douketis J J Thromb Haemost; 2012 Jun; 10(6):1019-25. PubMed ID: 22489957 [TBL] [Abstract][Full Text] [Related]
50. Safety of excluding acute pulmonary embolism based on an unlikely clinical probability by the Wells rule and normal D-dimer concentration: a meta-analysis. Pasha SM; Klok FA; Snoep JD; Mos IC; Goekoop RJ; Rodger MA; Huisman MV Thromb Res; 2010 Apr; 125(4):e123-7. PubMed ID: 19942258 [TBL] [Abstract][Full Text] [Related]
51. The benefit of D-Dimer testing to decide on stopping anticoagulation after a first unprovoked VTE: a matter of sex or of test sensitivity? Czihal M; Reinecke H Vasa; 2015 Sep; 44(5):399. PubMed ID: 26317262 [No Abstract] [Full Text] [Related]
53. D-dimer levels correlate with mortality in patients with acute pulmonary embolism: Findings from the RIETE registry. Grau E; Tenías JM; Soto MJ; Gutierrez MR; Lecumberri R; Pérez JL; Tiberio G; Crit Care Med; 2007 Aug; 35(8):1937-41. PubMed ID: 17581488 [TBL] [Abstract][Full Text] [Related]
54. Should D-dimer testing be used to predict the risk of recurrence after discontinuation of anticoagulant therapy for a first unprovoked episode of venous thromboembolism? Wu C; Bates SM Pol Arch Med Wewn; 2009 Apr; 119(4):225-30. PubMed ID: 19413181 [TBL] [Abstract][Full Text] [Related]
55. Aspirin for preventing the recurrence of venous thromboembolism. Becattini C; Agnelli G; Schenone A; Eichinger S; Bucherini E; Silingardi M; Bianchi M; Moia M; Ageno W; Vandelli MR; Grandone E; Prandoni P; N Engl J Med; 2012 May; 366(21):1959-67. PubMed ID: 22621626 [TBL] [Abstract][Full Text] [Related]
56. Duration of anticoagulation therapy for venous thromboembolism. Bounameaux H; Perrier A Hematology Am Soc Hematol Educ Program; 2008; ():252-8. PubMed ID: 19074092 [TBL] [Abstract][Full Text] [Related]
57. "HERDOO2" clinical decision rule to guide duration of anticoagulation in women with unprovoked venous thromboembolism. Can I use any d-Dimer? Rodger MA; Le Gal G; Langlois NJ; Gin B; Mallick R; Giulivi A; Freedman M; Kovacs MJ; Thromb Res; 2018 Sep; 169():82-86. PubMed ID: 30031290 [TBL] [Abstract][Full Text] [Related]
58. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). Franco Moreno AI; García Navarro MJ; Ortiz Sánchez J; Martín Díaz RM; Madroñal Cerezo E; de Ancos Aracil CL; Cabello Clotet N; Perales Fraile I; Gimeno García S; Montero Hernández C; Zapatero Gaviria A; Ruiz Giardín JM Eur J Intern Med; 2016 Apr; 29():59-64. PubMed ID: 26775136 [TBL] [Abstract][Full Text] [Related]
59. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120 [TBL] [Abstract][Full Text] [Related]
60. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated. Kearon C J Thromb Thrombolysis; 2011 Apr; 31(3):295-300. PubMed ID: 21331558 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]